Data comp: RSV prophylactics for infants
An FDA advisory committee this week will evaluate Pfizer’s Abrysvo vaccine, one of two infant RSV interventions up for FDA approval this year
Two very different interventions are under FDA review to protect infants from RSV, and a look at their data side by side suggests it may be challenging for parents and physicians to decide which is more effective.
First up is a BLA from Pfizer Inc. (NASDAQ:PFE) for Abrysvo (RSVpreF), a vaccine against respiratory syncytial virus (RSV) infection. FDA’s Vaccines and Related Biological Products Advisory Committee will meet on Thursday to discuss the application, which is the first to seek approval of a vaccine developed specifically for immunization of pregnant women — a setting where the bar for safety will be high. Unmet need will likely also play into the decision...